Tag Archive for: clinical data

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

/in

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance Montreal, Canada – Strasbourg, France – Boston, United States, March 10, 2026: Kainova Therapeutics (“the Company”), a key player for breakthrough treatments in immuno-oncology and inflammation, today […]

Read more

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

/in

Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR) with associated macular edema Oral treatment was well tolerated, showed signs of clinical effect and retinal imaging data consistent with reductions in vascular leakage, one of the core […]

Read more

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025

/in

New clinical data from the MATCH Phase II study shows early improvement in liver function after treatment with non-engineered macrophages is associated with positive long term clinical outcomes New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation Comes as Resolution progresses its Phase I/II EMERALD study of […]

Read more

Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma

/in

Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8 HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed in Cohort 8 R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST) Ladenburg, Germany, 6 November 2025 […]

Read more

Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration

/in

Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises levels of progranulin in people who have a shortage of this vital protein for genetic reasons, potentially stopping them developing symptomatic frontotemporal dementia (FTD) […]

Read more